Endo Partners With US Government On Critical Medicines
Par Unit Will Expand Sterile Fill-Finish Manufacturing Capacity At Its Rochester Facility
Endo subsidiary Par Sterile Products will expand its Rochester, Michigan facility to begin the fill-finish manufacturing of both mRNA and adenovirus vaccines. Around three-quarters of the project’s expected $120m total costs are being funded by the US government as part of larger efforts to boost the country’s domestic supply of essential medicines.
